These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 11192299)

  • 1. Immunological responses in patients who have spontaneously eradicated hepatitis C virus infection.
    Zitron IM; Laurinaitis M; Qu L; Silverman AL; Gordon SC
    Viral Immunol; 2000; 13(4):521-31. PubMed ID: 11192299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis of hepatitis C virus in Brazilian blood donors using a reverse transcriptase nested polymerase chain reaction: comparison with enzyme immunoassay and recombinant protein immunoblot assay.
    Gonçales NS; Costa FF; Vassallo J; Gonçales FL
    Rev Inst Med Trop Sao Paulo; 2000; 42(5):263-7. PubMed ID: 11058936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection.
    Conry-Cantilena C; VanRaden M; Gibble J; Melpolder J; Shakil AO; Viladomiu L; Cheung L; DiBisceglie A; Hoofnagle J; Shih JW
    N Engl J Med; 1996 Jun; 334(26):1691-6. PubMed ID: 8637513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiological, biological and histological characterization of patients with indeterminate third-generation recombinant immunoblot assay antibody results for hepatitis C virus.
    Ríos M; Diago M; Rivera P; Tuset C; Cors R; García V; Carbonel P; Gonzalez C
    J Viral Hepat; 2006 Mar; 13(3):177-81. PubMed ID: 16475993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relation between reactivity to the NS-4 region peptides of hepatitis C virus (HCV) and clinical features among patients infected with HCV genotype 1b.
    Sakugawa H; Nakasone H; Nakayoshi T; Kawakami Y; Kinjo F; Saito A; Nakayoshi T; Yamashiro A
    Microbiol Immunol; 1998; 42(4):299-303. PubMed ID: 9623917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative antibody responses to structural (Core) and nonstructural (NS3, NS4, and NS5) hepatitis C virus proteins among seroconverting injecting drug users: impact of epitope variation and relationship to detection of HCV RNA in blood.
    Beld M; Penning M; van Putten M; Lukashov V; van den Hoek A; McMorrow M; Goudsmit J
    Hepatology; 1999 Apr; 29(4):1288-98. PubMed ID: 10094977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring antibody titers to recombinant Core-NS3 fusion polypeptide is useful for evaluating hepatitis C virus infection and responses to interferon-alpha therapy.
    Park YM; Byun BH; Choi JY; Bae SH; Kim BS; So HS; Ryu WS
    J Korean Med Sci; 1999 Apr; 14(2):165-70. PubMed ID: 10331562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical relevance of persistent recombinant immunoblot assay-indeterminate reactions: insights into the natural history of hepatitis C virus infection and implications for donor counseling.
    Makuria AT; Raghuraman S; Burbelo PD; Cantilena CC; Allison RD; Gibble J; Rehermann B; Alter HJ
    Transfusion; 2012 Sep; 52(9):1940-8. PubMed ID: 22304422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of hepatitis C virus infection with recombinant immunoblot assay, synthetic immunoblot assay, and polymerase chain reaction.
    Chaudhary RK; Andonov A; MacLean C
    J Clin Lab Anal; 1993; 7(3):164-7. PubMed ID: 7685380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indeterminate third-generation hepatitis C recombinant immunoblot assay and HCV RNA analysis: isolated reactivity against NS5 associated with HCV viraemia in clinical patients but not blood donors.
    Cavazza S; Lagging M
    Scand J Infect Dis; 2005; 37(6-7):488-92. PubMed ID: 16012009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection.
    Lehmann M; Meyer MF; Monazahian M; Tillmann HL; Manns MP; Wedemeyer H
    J Med Virol; 2004 Jul; 73(3):387-91. PubMed ID: 15170633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of indeterminate third-generation hepatitis C virus recombinant immunoblot assay.
    Pawlotsky JM; Bastie A; Pellet C; Remire J; Darthuy F; Wolfe L; Sayada C; Duval J; Dhumeaux D
    J Clin Microbiol; 1996 Jan; 34(1):80-3. PubMed ID: 8748278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diverse patterns of recognition of hepatitis C virus core and nonstructural antigens by antibodies present in Egyptian cancer patients and blood donors.
    Attia MA; Zekri AR; Goudsmit J; Boom R; Khaled HM; Mansour MT; de Wolf F; el-Din HM; Sol CJ
    J Clin Microbiol; 1996 Nov; 34(11):2665-9. PubMed ID: 8897161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of differential antibody production against hepatitis C virus in different HCV infection status.
    Rafik M; Bakr S; Soliman D; Mohammed N; Ragab D; ElHady WA; Samir N
    Virol J; 2016 Jun; 13():116. PubMed ID: 27357382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is it possible to diagnose acute hepatitis C virus (HCV) infection by a rising anti-HCV titre rather than by seroconversion?
    Lu SN; Tung HD; Chen TM; Lee CM; Wang JH; Hung CH; Chen CH; Changchien CS
    J Viral Hepat; 2004 Nov; 11(6):563-70. PubMed ID: 15500558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of highly positive c22-3 "indeterminate" second-generation hepatitis C virus (HCV) recombinant immunoblot assay (RIBA) and resolution by third-generation HCV RIBA.
    Pawlotsky JM; Fleury A; Choukroun V; Deforges L; Roudot-Thoraval F; Aumont P; Duval J; Dhumeaux D
    J Clin Microbiol; 1994 May; 32(5):1357-9. PubMed ID: 7519631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of production of virus-specific interferon-gamma among seronegative hepatitis C-resistant subjects reporting injection drug use.
    Freeman AJ; Ffrench RA; Post JJ; Harvey CE; Gilmour SJ; White PA; Marinos G; van Beek I; Rawlinson WD; Lloyd AR
    J Infect Dis; 2004 Sep; 190(6):1093-7. PubMed ID: 15319859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Supplementary anti-hepatitis C virus (HCV) testing with 2nd and 3rd generation recombinant immunoblot assay and matrix applied to enzyme immunoassay positive sera and comparison with HCV-RNA detection.
    Engel PM; Dennin RH
    Zentralbl Bakteriol; 1998 Oct; 288(2):267-75. PubMed ID: 9809407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of anti-hepatitis C virus antibodies in patients undergoing dialysis by utilizing a hepatitis C virus 3.0 assay: correlation with hepatitis C virus RNA.
    de Medina M; Hill M; Sullivan HO; Leclerq B; Pennell JP; Jeffers L; Reddy KR; Schiff ER; Perez GO
    J Lab Clin Med; 1998 Jul; 132(1):73-5. PubMed ID: 9665375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in hepatitis C virus (HCV) antibody status in patients with chronic hepatitis C after eradication of HCV infection by interferon therapy.
    Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Kuzuya T; Honda T; Hayashi K; Nakano I; Katano Y; Goto H
    Clin Infect Dis; 2005 Mar; 40(6):e49-54. PubMed ID: 15736006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.